<DOC>
	<DOC>NCT01018745</DOC>
	<brief_summary>The purpose of this clinical study is to establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (or dose range as appropriate) of BMS-907351 (XL184) when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors.</brief_summary>
	<brief_title>Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan</brief_title>
	<detailed_description />
	<criteria>Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate Life expectancy of at least 3 months Eastern Cooperative Oncology Group performance 02 Subject has uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>